27th February 2020 (Presentation)
USCOM 1A, Coronavirus and Sepsis Seasonal flu in America – 2017-18 – Infections ~ 45M, Hospitalisation ~810,000, Mortality ~61,000
This is not a coronavirus story but a seasonal infection story that is on going and an innovative Australian Medical Device Company is at the centre of its successful treatment. Uscom has spent 20 years committed to the development of devices and management strategies to improve care of patients from neonates to the elderly with sepsis
Uscom technology is saving the lives of children and adults around the world daily and has now been specifically recommended by the Chinese Government Coronavirus Guidelines and international Sepsis Guidelines for Children for treatment of serious infections.
Severe COVID-19
Pneumonia
Sepsis – infection poisons body and organs, particularly heart, vessels and lungs
Death – from organ (cardiovascular and pulmonary) failure
Treatment
No vaccine
Circulatory Support:
Cardiovascular system– fluid, Inotropes and vasoactives (USCOM 1A Guided); Respiratory system– ventilation and ECMO
Immune defence - recovery
COVID-19 patients die from cardiovascular pulmonary failure Uscom specializes in non-invasive cardiovascular and pulmonary monitoring devices
USCOM 1A
Provides accurate diagnosis of cardiovascular disease and can simply guide appropriate therapy!
Can be used in newborns to 100 years with normal values across all ages with treatment protocols
...
USCOM 1A is the only globally available Doppler Haemodynamic Monitor and is specialised for management of sepsis
...
